[ad_1]
Speaking on the Andrew Marr Show on the BBC Prof. Dr. Uğur ŞahinBy stating that you are confident that with such an effective vaccine, human-to-human transmission will decrease perhaps not by 90 percent, but by 50 percent, even this will significantly reduce the spread of the pandemic.
CORONAVIRUS NEWS
Stating that if all goes well, the vaccine will begin shipping late this winter or early next year, Şahin said his goal is to distribute at least 300 million doses worldwide by April.
Emphasizing that he can return to normal life next winter, Şahin noted that it is important to complete the entire vaccination program before next fall.
Noting that the summer months will also help fight the virus by decreasing infection rates, Şahin said a high level of vaccination needs to be achieved in the fall of next year.
Noting that the side effects of the vaccine were pain that lasted a few days at the site where the vaccine was given and a mild fever that lasted a few days in some subjects, Şahin said that they found no serious side effect that stopped or paused the study.
Reported to be more than 90 percent effective
The American pharmaceutical company Pfizer and the Turkish scientist Prof. Dr. The possible vaccine developed by the German biotechnology company BioNTech, of which Uğur Şahin was a founding partner, was reported to be more than 90 percent effective against the virus.
It was announced that the candidate vaccine BNT162b1 has been tested in 43,538 people in 6 countries, and there have been no serious safety issues in the trials so far.
As countries around the world compete to sign contracts for millions of vaccine doses, BioNTech previously announced plans to produce 100 million more vaccines globally by the end of 2020 and about 1.3 billion more doses by the end of 2021.
Pfizer and BioNTech signed a preliminary agreement with the US, EU, UK, Canada and Japan for the supply of the vaccine.
The companies had signed a $ 1.95 billion contract to provide 100 million doses of vaccines to the United States government this year.
The EU Commission announced yesterday that the Commission will soon sign contracts with these companies to receive up to 300 million doses of vaccine.
The EU had previously signed contracts with the pharmaceutical companies Johnson and Johnson, AstraZeneca and Sanofi-GSK to purchase vaccines, and also announced that the vaccine purchase negotiations with the companies CureVac, BioNTech-Pfizer and Moderna were successful.
News presented to subscribers through the AA News Flow System (HAS) is published on the Anadolu Agency website in summary form. Get in touch to subscribe.
[ad_2]
